PYC Therapeutics (ASX:PYC), a biotechnology company developing a new generation of precision RNA therapeutics, has announced the appointment of Dr Glenn Noronha as its chief development officer.
The company said Dr Noronha will oversee its translational clinical development, regulatory, manufacturing and preclinical development activities as it develops its drug candidates that are initially focused on inherited ocular diseases.
Dr Noronha has over 20 years of experience across both small and large biotechnology and pharmaceutical companies, with particular expertise in the development of ophthalmology drug candidates through positions at BridgeBio Pharma, Clearside Biomedical and Alcon.
The company said Dr Noronha has been involved in eight Investigational New Drug (IND) applications and 3 New Drug Applications (NDA) with the US FDA.
“Glenn brings an unparalleled depth of experience in ophthalmology to our growing US leadership team, along with a demonstrable history of success in building teams, creating and executing drug development strategy from pre-Investigational New Drug (IND) through commercialisation, and his appointment strengthens the executive leadership team by adding significant operational expertise,” said Sahm Nasseri, US CEO of PYC Therapeutics.
“He will play an essential role in transforming PYC into a clinical-stage company as we progress our pipeline development programs, including VP-001, our lead candidate for retinitis pigmentosa type 11.”
“I am thrilled to join PYC at such a pivotal time as the Company, which is initially targeting inherited ocular diseases, builds its presence in the U.S. and advances its pioneering RNA therapeutics pipeline toward clinical development,” said Dr Noronha.
“I have dedicated my career to developing therapies for ophthalmology patients with conditions where there is unmet or underserved need, and I am excited to collaborate with the dynamic PYC team that also prioritizes this goal.”